BlissBio announced that its Investigational New Drug (IND) application for the innovative antibody-drug conjugate (ADC) BB-1712 has been approved by the National Medical Products Administration (NMPA) of China. BB-1712, a B7-H3 targeted ADC utilizing Eribulin as its cytotoxic agent, has been developed for the treatment of multiple solid tumors, signifying a crucial advancement in oncology therapeutics.
Company Overview: A Commitment to Oncological Innovations
Founded in December 2017 in Hangzhou, Bliss Biopharmaceutical Co., Ltd. (“BlissBio”) has rapidly evolved into a clinical-stage biotech company focused on the discovery, development, and commercialization of oncological biological therapeutics. Currently, BlissBio is advancing multiple innovative tumor-targeting ADCs through Phase I and Phase II clinical trials, each showcasing substantial market potential for various cancer types.
Expertise and Collaborative Efforts Driving Success
The core team at BlissBio possesses a proven track record in the research, development, and industrialization of diverse products within the realm of oncology. The company boasts a variety of robust technology platforms, a rich pipeline at multiple development stages, and facilities capable of manufacturing antibodies and ADCs that comply with international GMP standards. Upholding the core value of “Together, We Improve Human Health,” BlissBio actively collaborates with both domestic and international partners to enhance the research, development, and industrialization of competitive innovative biologics.-Fineline Info & Tech
Leave a Reply